Prosensa Strengthens its Management Team: Berndt Modig appointed as Chief Financial Officer

18-Mar-2010 - Netherlands

Prosensa announced the appointment of Berndt Modig as Chief Financial Officer (CFO).

Berndt Modig (51) brings more than 20 years of international experience in company finance to Prosensa. In his previous position as CFO of Jerini AG, a German drug discovery and development company, he managed several financing operations, including the company’s IPO on the Frankfurt stock exchange. He also co-ordinated the acquisition of Jerini by Shire. Before this, Berndt was CFO at Surplex AG and Finance Director Europe of Hayward Industrial Products GmbH, a European subsidiary of Hayward Industries Inc. As co-founder and partner in Agra Industria Sprl and investment manager at IMM GmbH he gained experience in private equity. He started his career at Price Waterhouse in the US where he held several positions in the Financial Services Group. Berndt has a Bachelor degree in Business Administration, Economics and German from the University of Lund, Sweden, an MBA from INSEAD, France and is a Certified Public Accountant.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis

Cell Receptor Recycling Mechanism Discovery opens up New Class of Therapeutic Targets